Genix Pharmaceuticals Corporation
GENX.V
TSX
| 01/31/2025 | 10/31/2024 | 07/31/2024 | 04/30/2024 | 01/31/2024 | |
|---|---|---|---|---|---|
| Net Income | 97.24% | 98.33% | -348.50% | -312.13% | -323.20% |
| Total Depreciation and Amortization | -- | -99.95% | -75.72% | -51.82% | -29.28% |
| Total Amortization of Deferred Charges | 0.00% | -25.00% | 50.00% | 25.00% | 0.00% |
| Total Other Non-Cash Items | -103.18% | -104.03% | 5,825.44% | 3,175.22% | 2,322.75% |
| Change in Net Operating Assets | 26.03% | -47.22% | -75.05% | -116.39% | 8.96% |
| Cash from Operations | 4.02% | 15.83% | 0.59% | 2.64% | 15.14% |
| Capital Expenditure | -- | -- | -- | -- | -- |
| Sale of Property, Plant, and Equipment | -- | -- | -- | -- | -- |
| Cash Acquisitions | -- | -- | -- | -- | -- |
| Divestitures | -- | -- | -- | -- | -- |
| Other Investing Activities | -- | -- | -- | -- | -- |
| Cash from Investing | -- | -- | -- | -- | -- |
| Total Debt Issued | 14.15% | -33.61% | -5.70% | -44.46% | -43.82% |
| Total Debt Repaid | -- | -- | 164.10% | 136.76% | 116.85% |
| Issuance of Common Stock | -- | -- | -- | -- | -- |
| Repurchase of Common Stock | -- | -- | -- | -- | -- |
| Issuance of Preferred Stock | -- | -- | -- | -- | -- |
| Repurchase of Preferred Stock | -- | -- | -- | -- | -- |
| Total Dividends Paid | -- | -- | -- | -- | -- |
| Other Financing Activities | -- | -- | 100.00% | 100.00% | 100.00% |
| Cash from Financing | 10.24% | -16.56% | 36.73% | -27.99% | -27.19% |
| Foreign Exchange rate Adjustments | -- | -- | -- | -- | -- |
| Miscellaneous Cash Flow Adjustments | -- | -- | -- | -- | -- |
| Net Change in Cash | 82.57% | -107.14% | 111.40% | -191.70% | -382.00% |